<DOC>
	<DOCNO>NCT00768326</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety Lu 31-130 patient suffer schizophrenia compare placebo .</brief_summary>
	<brief_title>Efficacy Lu 31-130 Patients With Schizophrenia</brief_title>
	<detailed_description>Schizophrenia serious disable mental disorder affect approximately 1 % world 's population . Antipsychotic drug remain cornerstone pharmacotherapy schizophrenia . However , none available drug ideal , particular complex safety profile limited effectiveness certain symptom disease . Thus , one dimension morbidity , , positive symptom , expect respond treatment whereas negative symptom cognitive deficit , best , marginally target . Given , doubt current antipsychotic drug leave much room improvement call new , effective pharmacotherapies treatment schizophrenia . In current study , patient suffer schizophrenia experience clinically significant symptom disease include . In current study , eligible patient randomise 2:1 ratio blind treatment either Lu 31-130 ( 3 , 5 , 7 , 10 14 mg/day ) placebo 8 week . The study include 5 part increase dos Lu 31-130 ( Part A [ 3 mg/day ] , B [ 5 mg/day ] , C [ 7 mg/day ] , D [ 10 mg/day ] , E [ 14 mg/day ] ) . A decision initiate Part B [ 5 mg/day Lu 31-130 ] , C [ 7 mg/day Lu 31-130 ] D [ 10 mg/day Lu 31-130 ] base safety tolerability previous study part . Dependent safety , tolerability PK data Part D study may proceed Part E. The efficacy safety Lu 31-130 evaluate comparison pool placebo group 5 study part .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>The patient primary diagnosis schizophrenia The patient experience clinically significant symptom The patient experience acute exacerbation require hospitalisation within last 6 month The patient 's medication stable least 4 week prior screen The subject normal serum value parameter associate liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Lu 31-130</keyword>
</DOC>